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Interim	  analysis	  31	  
 32	  
One interim analysis was planned and conducted to examine the efficacy of ISTp-DP versus 33	  
IPTp-SP, with the plan to stop the ISTp-DP arm only (not the whole trial) if ISTp-DP is 34	  
significantly less efficacious than IPTp-SP. This was conducted after 777 completed 35	  
deliveries (half of the proposed total sample size). As per protocol, the main outcome was the 36	  
presence or absence of malaria infection at the time of delivery (the composite of peripheral 37	  
and placental parasitemia), detected by placental histology, positive peripheral blood smear at 38	  
the time of delivery, or positive RDT at the time of delivery. A two-sided Pearson’s chi-39	  
square exact test at alpha = 0.000824 (O’Brien-Fleming spending function) was used to 40	  
compare the ISTp-DP arm versus the IPTp-SP arm. The interim analysis resulted in a p-value 41	  
of 0.77 that is not close to the O’Brien-Fleming spending function of alpha = 0.000824. Thus, 42	  
the ISTp-DP arm was not stopped. The final analyses were tested at a significance level of 43	  
0.025 - 0.000824 = 0.024176 to decide whether or not we rejected the respective null 44	  
hypotheses for the comparison between ISTp-DP and IPTp-SP using a 2-sided p-value.  45	  
Endpoint	  definitions	  46	  
Malaria	  infection	  endpoints	  47	  
While the primary malaria infection endpoint excluded PCR and past infections by histology, 48	  
secondary malaria infection endpoints included consideration of PCR and past infections, the 49	  
latter defined as malaria pigment in the absence of parasites on histology. 50	  
Morbidity	  endpoints	  51	  
Birthweight data 52	  
The aim of the study was to measure birthweight within 24 hours after birth. Birth weights 53	  
taken 24-48h hours (n= 39, 2.6%), and 48-168 hours after delivery (n= 5, 0.3%) were 54	  
corrected for the physiological fall in birth weight in breastfed infants occurring in the first 55	  
days following delivery1, 2 by a factor +2% and +4%, respectively to obtain the estimated 56	  
weight at birth.3, 4  All analyses used corrected birthweight unless indicated otherwise. Low 57	  
birth weight was defined as <2,500 grams. 58	  
Gestational age and preterm 59	  
If more than one gestational age measurement was available we used estimates in the 60	  
following order of preference: neonatal clinical exam within 96 hours of delivery (Ballard 61	  
score), last menstrual period (if known), and fundal height at enrolment. Preterm was defined 62	  
as a gestational age of less than 37 completed weeks.  63	  
Small for gestational age (SGA) 64	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SGA was defined as birthweight below the tenth percentile for a given gestational age and 65	  
sex, using a reference population from Tanzania population was used, as ultrasound-based 66	  
fetal growth charts were not available for Kenyan populations. This also allowed the 67	  
calculation of Z-scores.5 68	  
Laboratory	  methods	  69	  
HIV serology was performed by the study health facilities as part of routine ANC profiling. 70	  
Syphilis serology was assessed according to Kenya Ministry of Health guidelines. 71	  
Hemoglobin levels were determined using portable HemoCue Hb 201+ (HemoCue AB, 72	  
Ängelholm Sweden) machines following manufacture instructions. Malaria rapid diagnostic 73	  
test (RDT) was performed as per the manufacturer’s instruction. Plasmodium falciparum 74	  
parasites identification and quantification by microscopy on Giemsa-stained thick and thin 75	  
peripheral blood smears were performed according to standard, quality-controlled 76	  
procedures. In brief, the blood smears were stained with 10% Giemsa for 15 minutes and 77	  
examined under oil immersion for malaria parasites.6, 7 A thick smear was considered 78	  
negative if 100 microscopic high powered fields showed no parasites. If thick smear was 79	  
positive, malaria parasites and white blood cells (WBC) were counted in the same fields until 80	  
a corresponding 500 WBCs were counted. Parasite densities per microliter of blood in the 81	  
thick blood smears were estimated using an assumed count of 8,000 WBC per microliter of 82	  
blood.6, 7 If the blood smear was positive for thin/impression smear, parasitized red blood cell 83	  
(pRBC) and red blood cells (RBCs) were counted in the same field until a corresponding 84	  
2000 RBCs were counted and expressed as parasites per microlitre of blood using an assumed 85	  
count of 4,500,000 RBCs per microliter of blood.6-8 All the blood films were read by 86	  
microscopists deemed competent through an external quality assurance programme provided 87	  
by the national institute of communicable diseases (NICD), South Africa.9 88	  
Real-time quantitative polymerase chain reaction (RT-qPCR) using P. falciparum-specific 89	  
primers and probes targeting P. falciparum 18S rRNA gene was performed on maternal 90	  
peripheral and placental samples, with the inclusion in all reactions of a positive standard and 91	  
a negative control with no template DNA. All the PCR assays were done from dried blood 92	  
spot (DBS) on a filter paper following standard operating procedures10, 11. The lower 93	  
detection limit of PCR was 5 parasites/uL of blood. Tissue samples collected from the 94	  
maternal side of the placenta and fixed with 10% neutral buffered formalin were processed, 95	  
stained, and examined following standard procedures.12 Giemsa-stained placental impression 96	  
smears were read following a standardized protocol.13 Women were screened for syphilis as 97	  
part of routine ANC care, using either RPR, VDRL or a Determine rapid diagnostic test kit 98	  
(on site). Those determined to be positive for syphilis were treated per national guidelines 99	  
with Benzathine Penicillin. 	  100	  
Analysis	  101	  
Pre-specified endpoints 102	  
The pre-specified endpoints included the primary endpoint of malaria infection at delivery 103	  
(composite or peripheral and placental parasitaemia), and several secondary endpoints: low 104	  
birthweight, small for gestational age, preterm births, maternal haemoglobin and anaemia, 105	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congenital malaria, incidence of malaria infection and all-cause sick visits by the mother and 106	  
infant, and serious adverse events in both the mothers and infants. 107	  
	  108	  
 109	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eResults	  
	  
Table	  S1:	  Follow-­‐up	  visits	  schedule	  (ITT)	  
Characteristic	   ISTp-­‐DP	   IPTp-­‐DP	   IPTp-­‐SP	  Achieved	  number	  of	  scheduled	  intervention	  visits	  (including	  enrolment,	  excluding	  delivery);	  	  n	  (%)	  	  1	  2	  3	  4	  5	  6	  7	  Total	  visits	  
	  	  	  	  39	  61	  172	  158	  76	  8	  1	  1738	  
	  	  	  	  32	  82	  175	  149	  63	  12	  1	  1705	  
	  	  	  	  31	  62	  172	  160	  71	  18	  0	  1774	  Number	  of	  DP	  or	  SP	  courses	  received;	  n	  (%)	  0	  1	  2	  3	  4	  5	  6	  Total	  courses	  received	  (all-­‐gravidae)	  Total	  courses	  received	  (paucigravidae)	  	  	  	  	  	  Median	  (range)	  	  	  	  	  	  Mean	  (SD)	  
	  348	  (67.6)	  140	  (27.2)	  27	  (5.2)	  0	  0	  0	  0	  194	  121	  0	  (0,	  2)	  0.45	  (0.61)	  
	  0	  (0)	  37	  (7.2)	  230	  (44.8)	  134	  (26.1)	  76	  (14.8)	  34	  (6.6)	  3	  (0.6)	  1391	  706	  2	  (1,	  6)	  2.68	  (1.08)	  
	  1	  (0.2)	  46	  (9.0)	  210	  (40.9)	  127	  (24.7)	  95	  (18.5)	  30	  (5.8)	  5	  (1.0)	  1407	  804	  3	  (1,	  6)	  2.75	  (1.07)	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Total	  courses	  received	  (multigravidae)	  	  	  	  	  	  Median	  (range)	  	  	  	  	  	  Mean	  (SD)	   73	  0	  (0,	  2)	  0.29	  (0.54)	   685	  2	  (1,	  6)	  2.73	  (1.03)	   603	  2	  (0,	  6)	  2.72	  (1.15)	  Number	  of	  women	  requiring	  AL	  for	  symptomatic	  malaria	  within	  4	  weeks	  of	  study	  dosing	   10	   5	   20	  Person	  weeks	  contributed	  till	  delivery	  or	  till	  lost	  to	  follow-­‐up,	  median	  (IQR)	   16.3	  (12.7,	  19.6)	   16.0	  (12.4,	  19.4)	   16.7	  	  (12.7,	  20.1)	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Table	  S2:	  Malaria	  at	  time	  of	  delivery	  (composite	  excluding	  PCR)	  by	  treatment	  group	  (adherence	  to	  protocol	  
population)	  	  ISTp-­‐DP	  
n/N	  (%)	  
IPTp-­‐DP	  
n/N	  (%)	  
IPTp-­‐SP	  
n/N	  (%)	  
	   PR/Difference	  
(95%CI),	  p-­‐value	  ISTp-­‐DP	  vs	  IPTp-­‐SP	   PR/Difference	  (95%CI),	  p-­‐value	  	  IPTp-­‐DP	  vs	  IPTp-­‐SP	   PR/Difference	  (95%CI),	  p-­‐value	  IPTp-­‐DP	  vs	  ISTp-­‐DP	  
All	  Gravidae	  
50/411	  (12.2)	   11/409	  (2.7)	   47/418	  (11.2)	   Unadjusted	  	  	   1.08	  (0.74,	  1.57)	  	  p=0.68	   0.24	  (0.13,	  0.46)	  p<0.0001	   0.22	  (0.12,	  0.42)	  p<0.0001	  Adjusted	  a	   1.05	  (0.70,	  1.58)	  p=0.80	   0.24	  (0.12,	  0.48)	  p<0.0001	   0.23	  (0.11,	  0.45)	  p<0.0001	  
Paucigravidae	  (G1+2)	  
32/206	  (15.5)	   8/211	  (3.8)	   34/235	  (14.5)	   Unadjusted	  	  	   1.07	  (0.69,	  1.68)	  p=0.75	   0.26	  (0.12,	  0.55)	  p=0.0004	   0.24	  (0.12,	  0.52)	  p=0.0002	  Adjusted	  a	   1.04	  (0.64,	  1.71)	  p=0.86	   0.27	  (0.12,	  0.62)	  p=0.0019	   0.26	  (0.12,	  0.60)	  p=0.0015	  
Multigravidae	  (G3+)	  
18/205	  	  (8.8)	   3/198	  (1.5)	   13/183	  (7.1)	   Unadjusted	  	  	   1.24	  (0.62,	  2.45)	  p=0.54	   0.21	  (0.06,	  0.74)	  p=0.0145	   0.17	  (0.05,	  0.58)	  p=0.0043	  Adjusted	  a	   1.14	  (0.55,	  2.37)	  p=0.72	   0.21	  (0.06,	  0.72)	  p=0.0138	   0.18	  (0.05,	  0.62)	  p=0.0063	  ATP	  cohort;	  a	  adjusted	  for	  site,	  gravidity	  (in	  pooled	  model),	  malaria	  at	  enrolment	  by	  PCR,	  rain/seasonality	  six	  months	  prior	  to	  delivery,	  ITN	  use,	  hb	  at	  enrolment,	  gestational	  age	  at	  enrolment,	  and	  educational	  status	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Table	  S3:	  Newborn	  outcome	  (composite	  LBW/SGA/PTB)	  by	  treatment	  group	  (adherence	  to	  protocol	  population)	  	  	  ISTp-­‐DP	  
n/N	  (%)	  
IPTp-­‐DP	  
n/N	  (%)	  
IPTp-­‐SP	  
n/N	  (%)	  
	   PR/Difference	  
(95%CI),	  p-­‐value	  ISTp-­‐DP	  vs	  IPTp-­‐SP	   PR/Difference	  (95%CI),	  p-­‐value	  	  IPTp-­‐DP	  vs	  IPTp-­‐SP	   PR/Difference	  (95%CI),	  p-­‐value	  IPTp-­‐DP	  vs	  ISTp-­‐DP	  
All	  Gravidae	  
52/412	  (12.6)	   42/402	  (10.5)	   40/413	  (9.7)	   Unadjusted	  	  	   1.30	  (0.88,	  1.92)	  p=0.18	   1.08	  (0.72,	  1.63)	  p=0.72	   0.83	  (0.56,	  1.21)	  p=0.33	  Adjusted	  a	   1.33	  (0.86,	  2.04)	  p=0.20	   0.88	  (0.55,	  1.42)	  p=0.60	   0.66	  (0.42,	  1.05)	  p=0.08	  
Paucigravidae	  (G1+2)	  
31/207	  (15.0)	   30/210	  (14.3)	   25/232	  (10.8)	   Unadjusted	  	  	   1.39	  (0.85,	  2.27)	  p=0.19	   1.33	  (0.81,	  2.18)	  p=0.27	   0.95	  (0.60,	  1.52)	  p=0.84	  Adjusted	  a	   1.40	  (0.81,	  2.43)	  p=0.24	   1.02	  (0.57,	  1.82)	  p=0.96	   0.73	  (0.41,	  1.28)	  p=0.27	  
Multigravidae	  (G3+)	  
21/205	  (10.2)	   12/192	  (6.3)	   15/181	  (8.3)	   Unadjusted	  	  	   1.24	  (0.66,	  2.32)	  p=0.51	   0.75	  (0.36,	  1.57)	  p=0.45	   0.61	  (0.31,	  1.21)	  p=0.16	  Adjusted	  a	   1.11	  (0.55,	  2.24)	  p=0.76	   0.60	  (0.26,	  1.38)	  p=0.23	   0.54	  (0.24,	  1.19)	  p=0.13	  ATP	  cohort;	  a	  adjusted	  for	  site,	  gravidity,	  malaria	  at	  enrolment	  by	  PCR,	  rain/seasonality	  six	  months	  prior	  to	  delivery,	  ITN	  use,	  hb	  at	  enrolment,	  gestational	  age	  at	  enrolment,	  and	  educational	  status	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Table	  S4a:	  Malaria	  related	  perinatal	  outcomes	  by	  treatment	  group	  (Paucigravidae) 	  
	   ISTp-­‐DP	  
n/N	  (%)or	  
N,	  mean	  
(SD)	  
IPTp-­‐DP	  
n/N	  (%)or	  
N,	  mean	  
(SD)	  
IPTp-­‐SP	  
n/N	  (%)or	  
N,	  mean	  
(SD)	  
Crude	  
PR/Difference	  
(95%CI),	  p-­‐value	  
ISTp-­‐DP	  vs	  IPTp-­‐
SP	  
Crude	  PR/Difference	  
(95%CI),	  p-­‐value	  	  
IPTp-­‐DP	  vs	  IPTp-­‐SP	  
Crude	  PR/Difference	  
(95%CI),	  p-­‐value	  
IPTp-­‐DP	  vs	  ISTp-­‐DP	  
Maternal Hb 3rd trimester 184,  
10.9 (1.5) 
181, 
11.2 (1.4) 
213, 
11.1 (1.6) 
-0.16 (-0.46, 0.14) 
p=0.29 
0.05 (-0.25, 0.35) 
p=0.74 
0.21 (-0.10, 0.52) 
p=0.18 
Maternal anemia 
(Hb<11g/dl) 3rd trimester 
89/184 
(48.4) 
80/181 
(44.2) 
100/213 
(47.0) 
1.03 (0.84, 1.27) 
p=0.78 
0.94 (0.76, 1.17) 
p=0.59 
0.91 (0.73, 1.14) 
p=0.43 
Maternal moderate anemia 
(Hb<9g/dl) 3rd trimester 
16/184 
(8.7) 
7/181 
(3.9) 
22/213 
(10.3) 
0.84 (0.46, 1.55) 
p=0.58 
0.37 (0.16, 0.86) 
p=0.0199 
0.44 (0.19, 1.06) 
p=0.07 
Maternal Hb, at delivery; 
mean (SD) 
211,  
11.6 (1.6) 
212, 
11.9 (1.5) 
244,  
11.7 (1.9) 
-0.06 (-0.36, 0.25) 
p=0.72 
0.21 (-0.10, 0.51) 
p=0.19 
0.26 (-0.06, 0.58) 
p=0.11 
Maternal anemia 
(Hb<11g/dl) at delivery 
70/211 
(33.2) 
54/212 
(25.5) 
83/244 
(34.0) 
0.98 (0.75, 1.26) 
p=0.85 
0.75 (0.56, 1.00) 
p=0.05 
0.77 (0.57, 1.04) 
p=0.08 
Maternal moderate anemia 
(Hb<9g/dl) at delivery 
11/211 
(5.2) 
5/212 
(2.4) 
11/244 
(4.5) 
1.16 (0.51, 2.61) 
p=0.73 
0.52 (0.18, 1.48) 
p=0.22 
0.45 (0.16, 1.28) 
p=0.13 
Malaria infection (3rd 
trimester) 
32/236 
(13.6) 
20/240 
(8.3) 
60/268 
(22.4) 
0.61 (0.41, 0.90) 
p=0.0121 
0.37 (0.23, 0.60) 
p<0.0001 
0.61 (0.36, 1.04) 
p=0.07 
Peripheral or placental 
malaria at delivery (any 
measure including PCR, 
excluding past infections) 
40/225 
(17.8) 
16/224 
(7.1) 
51/258 
(19.8) 
0.90 (0.62, 1.31) 
p=0.58 
0.36 (0.21, 0.62) 
p=0.0002 
0.40 (0.23, 0.70) 
p=0.0011 
Maternal peripheral malaria 
infection (at delivery, any 
measure) 
34/225 
(15.1) 
10/224 
(4.5) 
37/258 
(14.3) 
1.05 (0.69, 1.62) 
p=0.81 
0.31 (0.16, 0.61) 
p=0.0007 
0.30 (0.15, 0.58) 
p=0.0004 
Placental malaria (any 
measure including	  PCR	  and	  
past	  infections	  on	  
histology) 
119/207 
(57.5) 
92/209 
(44.0) 
121/242 
(50.0) 
1.15 (0.97, 1.37) 
p=0.11 
0.88 (0.72, 1.07) 
p=0.21 
0.77 (0.63, 0.93) 
p=0.0066 
Peripheral or placental 
malaria at delivery (any 
measure including PCR and	  
past	  infections	  on	  
histology) 
124/225 
(55.1) 
93/224 
(41.5) 
123/258 
(47.7) 
1.16 (0.97, 1.38) 
p=0.10 
0.87 (0.71, 1.07) 
p=0.18 
0.75 (0.62, 0.92) 
p=0.0044 
Fetal cord Hb (mean, SD) 200, 
14.3 (2.4) 
204,  
14.5 (2.4) 
231, 
14.6 (2.9) 
-0.37 (-0.86, 0.11) 
p=0.13 
-0.18 (-0.67, 0.30) 
p=0.46 
0.19 (-0.31, 0.69) 
p=0.45 
Fetal anemia 
(Hb<12.5g/dl cord blood) 
35/200 
(17.5) 
42/204 
(20.6) 
42/231 
(18.1) 
0.96 (0.64, 1.44) 
p=0.85 
1.13 (0.77, 1.66) 
p=0.53 
1.18 (0.79, 1.76) 
p=0.43 
Birthweight 
(mean, SD) 
3138.1 
(444.7) 
3110.7 
(450.2) 
3201.0 
(456.1) 
-62.9 (-147.4, 
21.7) 
p=0.15 
-90.2 (-174.7, -5.8) 
p=0.0362 
-27.4 (-114.5, 59.8) 
p=0.54 
Corrected birthweight 
(mean, SD) 
3139.7 
(444.7) 
3115.1 
(448.5) 
3201.8 
(455.0) 
-62.2 (-146.0, 
21.6) 
-86.7 (-170.5, -2.9) 
p=0.0425 
-24.5 (-110.5, 61.5) 
p=0.58 
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p=0.15 
Gestational age at birth 
(weeks) 
225 
38.8 (1.8) 
223, 
38.8 (2.3) 
255, 
39.0 (1.9) 
-0.21 (-0.57, 0.15) 
p=0.25 
-0.18 (-0.54, 0.18) 
p=0.32 
0.03 (-0.34, 0.40) 
p=0.88 
Birthweight for gestational 
age (Z-score) 
212, 
0.27 
(1.01) 
211, 
0.18 (0.95) 
240, 
0.37 (1.02) 
-0.09 (-0.28, 0.09) 
p=0.31 
-0.19 (-0.37, -0.002) 
p=0.0478 
-0.09 (-0.28, 0.10) 
p=0.35 
Small-for-gestational age 
(SGA) 
21/212  
(9.9) 
17/211 
(8.1) 
18/240 
(7.5) 
1.32 (0.72, 2.41) 
p=0.36 
1.07 (0.57, 2.03) 
p=0.83 
0.81 (0.44, 1.50) 
p=0.51 
Low Birthweight (LBW) 11/209 
(5.3) 
16/209 
(7.7) 
13/233 
(5.6) 
0.94 (0.43, 2.06) 
p=0.88 
1.37 (0.68, 2.78) 
p=0.38 
1.45 (0.69, 3.06) 
p=0.32 
Preterm birth 
(PTB) 
16/225 
(7.1) 
15/223 
(6.7) 
10/255 
(3.9) 
1.81 (0.84, 3.91) 
p=0.13 
1.72 (0.79, 3.74) 
p=0.18 
0.95 (0.48, 1.87) 
p=0.87 
Still birth 3/225 
(1.3) 
1/224 
(0.5) 
10/255 
(3.9) 
0.34 (0.09, 1.22) 
p=0.10 
0.11 (0.01, 0.88) 
p=0.0375 
0.33 (0.04, 3.19) 
p=0.34 
Fetal loss 4/225 
(1.8) 
3/224 
(1.3) 
11/255 
(4.3) 
0.41 (0.13, 1.28) 
p=0.12 
0.31 (0.09, 1.10) 
p=0.07 
0.75 (0.17, 3.33) 
p=0.71 
Any adverse birth outcome 35/225 
(15.6) 
31/224 
(13.8) 
35/256 
(13.7) 
1.14 (0.74, 1.75) 
p=0.56 
1.01 (0.65, 1.59) 
p=0.96 
0.89 (0.57, 1.39) 
p=0.61 
Congenital malaria 
infection 
4/267 
(1.50) 
2/261 
(0.77) 
0/290 
(0.0) 
Not applicable Not applicable	   Not applicable	  
Infant clinical malaria by 6-
8wks (cumulative) 
1/174 
(0.6) 
4/176 
(2.3) 
4/198 
(2.0) 
0.29 (0.03, 2.60) 
p=0.27 
1.12 (0.28, 4.47) 
p=0.88 
3.85 (0.43, 34.5) 
p=0.23 
Neonatal death 4/225	  (1.8) 4/224	  (1.8) 8/255	  (3.1) 0.57	  (0.17,	  1.86)	  p=0.35 0.57	  (0.17,	  1.86)	  p=0.35 1.00	  (0.25,	  3.97)	  p=0.99 
Perinatal death 7/225	  (3.1) 5/224	  (2.2) 17/255	  (6.7) 0.47	  (0.20,	  1.10)	  p=0.08 0.33	  (0.13,	  0.89)	  p=0.0288 0.72	  (0.23,	  2.23)	  p=0.57 
Infant deaths by 6-8wks 
(end of follow up) 
4/225	  (1.8) 4/224	  (1.8) 8/255	  (3.1) 0.57	  (0.17,	  1.86)	  p=0.35 0.57	  (0.17,	  1.86)	  p=0.35 1.00	  (0.25,	  3.97)	  p=0.99 ITT	  cohort;	  a	  spontaneous	  abortion	  or	  stillbirth;	  b	  SGA/LBW/PTB	  or	  fetal	  loss	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Table	  S4b:	  Malaria	  related	  perinatal	  outcomes	  by	  treatment	  group	  (Multigravidae	  
G3+)	  
	   ISTp-­‐DP	  
n/N	  
(%)or	  
N,	  mean	  
(SD)	  
IPTp-­‐DP	  
n/N	  
(%)or	  
N,	  mean	  
(SD)	  
IPTp-­‐SP	  
n/N	  (%)or	  
N,	  mean	  
(SD)	  
Crude	  
PR/Difference	  
(95%CI),	  p-­‐
value	  ISTp-­‐DP	  vs	  IPTp-­‐SP	  
Crude	  
PR/Difference	  
(95%CI),	  p-­‐
value	  	  IPTp-­‐DP	  vs	  IPTp-­‐SP	  
Crude	  
PR/Difference	  
(95%CI),	  p-­‐value	  IPTp-­‐DP	  vs	  ISTp-­‐DP	  
Maternal Hb 
(mean, SD), 3rd trimester 
200,  
11.0 (1.3) 
189, 
10.8 (1.4) 
162, 
11.0 (1.4) 
0.05 (-0.24, 0.33) 
p=0.75 
-0.13 (-0.42, 
0.15) 
p=0.36 
-0.18 (-0.45, 0.09) 
p=0.19 
Maternal anemia 
(Hb<11g/dl) 3rd trimester 
87/200 
(43.5) 
106/189 
(56.1) 
76/162 
(46.9) 
0.93 (0.74, 1.16) 
p=0.52 
1.20 (0.97, 1.47) 
p=0.09 
1.29 (1.05, 1.58) 
p=0.0138 
Maternal moderate anemia 
(Hb<9g/dl) 3rd trimester 
14/200 
(7.0) 
14/189 
(7.4) 
9/162 
(5.6) 
1.26 (0.56, 2.84) 
p=0.58 
1.33 (0.59, 3.00) 
p=0.49 
1.06 (0.52, 2.16) 
p=0.88 
Maternal Hb, at delivery; N, 
mean (SD) 
210,  
11.5 (1.5) 
214,  
11.5 (1.6) 
183, 
11.4 (1.4) 
0.12 (-0.18, 0.42) 
p=0.44 
0.11 (-0.19, 
0.41) 
p=0.48 
-0.01 (-0.30, 0.28) 
p=0.93 
Maternal anemia 
(Hb<11g/dl) at delivery 
72/210 
(34.3) 
61/214 
(28.5) 
64/183 
(35.0) 
0.98 (0.75, 1.29) 
p=0.89 
0.82 (0.61, 1.09) 
p=0.17 
0.83 (0.63, 1.10) 
p=0.20 
Maternal moderate anemia 
(Hb<9g/dl) at delivery 
9/210 
(4.3) 
14/214 
(6.5) 
9/183 
(4.9) 
0.87 (0.35, 2.15) 
p=0.77 
1.33 (0.59, 3.00) 
p=0.49 
1.53 (0.68, 3.45) 
p=0.31 
Malaria infection (3rd 
trimester) 
43/237 
(18.1) 
14/238 
(5.9) 
30/202 
(14.9) 
1.22 (0.80, 1.87) 
p=0.36 
0.40 (0.22, 0.73) 
p=0.0027 
0.32 (0.18, 0.58) 
p=0.0001 
Peripheral or placental 
malaria at delivery (any 
measure including PCR, 
excluding past infections) 
39/227 
(17.2) 
10/233 
(4.3) 
22/201 
(11.0) 
1.57 (0.96, 2.55) 
p=0.07 
0.39 (0.19, 0.81) 
p=0.0112 
0.25 (0.13, 0.49) 
p<0.0001 
Maternal peripheral malaria 
infection (at delivery, any 
measure) 
31/227  
(13.7) 
6/233 
(2.6) 
17/201 
(8.5) 
1.61 (0.92, 2.83) 
p=0.09 
0.30 (0.12, 0.76) 
p=0.0105 
0.19 (0.08, 0.44) 
p=0.0001 
Placental malaria (any 
measure including	  PCR	  and	  
past	  infections	  on	  histology) 
71/207 
(34.3) 
47/212 
(22.2) 
38/184 
(20.7) 
1.66 (1.18, 2.33) 
p=0.0035 
1.07 (0.73, 1.57) 
p=0.71 
0.65 (0.47, 0.89) 
p=0.0066 
Peripheral or placental 
malaria at delivery (any 
measure including PCR and	  
past	  infections	  on	  histology) 
75/227 
(33.0) 
47/233 
(20.2) 
43/201 
(21.4) 
1.54 (1.12, 2.13) 
p=0.0084 
0.94 (0.65, 1.36) 
p=0.75 
0.61 (0.45, 0.84) 
p=0.0022 
Fetal cord Hb (mean, SD) 200, 
14.0 (2.4) 
197, 
14.1 (2.2) 
172, 
14.1 (2.2) 
-0.15 (-0.61, 0.31) 
p=0.53 
-0.02 (-0.49, 
0.44) 
p=0.92 
0.13 (-0.32, 0.57) 
p=0.58 
Fetal anemia 
(Hb<12.5g/dl cord blood) 
45/200 
(22.5) 
39/197 
(19.8) 
34/172 
(19.8) 
1.14 (0.77, 1.69) 
p=0.52 
1.0 (0.66, 
1.51) 
p=0.99 
0.88 (0.60, 1.29) 
p=0.51 
Birthweight 
(mean, SD) 
3320.5 
(502.5) 
3255.0 
(395.0) 
3365.0 
(447.1) 
-44.5 (-136.4, 
47.4) 
p=0.34 
-110.0 (-201.7, -
18.3) 
p=0.0188 
-65.5 (-153.5, 22.5) 
p=0.14 
Corrected birthweight 
(mean, SD) 
3330.6 
(503.9) 
3262.6 
(404.4) 
3372.9 
(457.0) 
-42.4 (-134.3, 
49.5) 
p=0.37 
-110.3 (-202.1, -
18.5) 
p=0.0185 
-67.9 (-156.2, 20.4) 
p=0.13 
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Gestational age at birth 
(weeks) 
226, 
39.3 (1.7) 
225, 
39.2 (2.0) 
196, 
39.3 (1.7) 
0.003 (-0.34, 
0.35) 
p=0.99 
-0.09 (-0.43, 
0.26) 
p=0.63 
-0.09 (-0.42, 0.24) 
p=0.60 
Birthweight for gestational 
age (Z-score) 
204, 
0.59 (1.14) 
206, 
0.40 (0.97) 
182, 
0.69 (1.11) 
-0.10 (-0.31, 0.12) 
p=0.37 
-0.29 (-0.50, -
0.07) 
p=0.0084 
-0.19 (-0.40, 0.02) 
p=0.07 
Small-for-gestational age 
(SGA) 
15/204 
(7.4) 
10/206 
(4.9) 
7/182 
(3.9) 
1.91 (0.80, 4.58) 
p=0.15 
1.26 (0.49, 3.25) 
p=0.63 
0.66 (0.30, 1.44) 
p=0.29 
Low Birthweight (LBW) 8/204 
(3.9) 
5/176 
(2.8) 
6/205 
(2.9) 
1.38 (0.46, 4.14) 
p=0.56 
1.03 (0.32, 3.32) 
p=0.96 
0.75 (0.26, 2.11) 
p=0.58 
Preterm birth 
(PTB) 
13/226 
(5.8) 
8/225 
(3.6) 
11/196 
(5.6) 
1.02 (0.47, 2.24) 
p=0.95 
0.63 (0.26, 1.54) 
p=0.32 
0.62 (0.26, 1.46) 
p=0.27 
Still birth 7/229 
(3.1) 
3/228 
(1.3) 
6/198 
(3.0) 
1.01 (0.34, 2.95) 
p=0.99 
0.43 (0.11, 1.71) 
p=0.23 
0.43 (0.11, 1.64) 
p=0.22 
Fetal loss 7/229 
(3.1) 
4/228 
(1.8) 
6/198 
(3.0) 
1.01 (0.34, 2.95) 
p=0.99 
0.58 (0.17, 2.02) 
p=0.39 
0.57 (0.17, 1.93) 
p=0.37 
Any adverse birth outcome 29/229 
(12.7) 
17/228 
(7.5) 
19/198 
(9.6) 
1.32 (0.76, 2.28) 
p=0.32 
0.78 (0.42, 1.45) 
p=0.43 
0.59 (0.33, 1.04) 
p=0.07 
Congenital malaria infection 1/247 
(0.4) 
0/243 
(0.0) 
0/218 
(0.0) 
Not applicable Not	  applicable	   Not	  applicable	  
Infant clinical malaria by 6-
8wks (cumulative) 
8/194 
(4.1) 
7/190 
(3.7) 
1/162 
(0.6) 
6.53 (0.82, 52.2) 
p=0.08 
5.74 (0.71, 46.7) 
p=0.10 
0.88 (0.32, 2.42) 
p=0.80 
Neonatal death 2/229 
(0.9) 
0/228 
(0.0) 
4/198 
(2.0) 
0.43	  (0.08,	  2.34)	  p=0.33	   Not applicable Not	  applicable	  
Perinatal death 9/229 
(3.9) 
3/228 
(1.3) 
10/198 
(5.1) 
0.78	  (0.32,	  1.88)	  p=0.58 0.26	  (0.07,	  0.93)	  
p=0.0388 
0.33	  (0.09,	  1.22)	  p=0.1 
Infant deaths by 6-8wks (end 
of follow up) 
2/229 
(0.9) 
0/228 
(0.0) 
5/198 
(2.5) 
0.35	  (0.07,	  1.76)	  p=0.20	   Not applicable Not	  applicable	  ITT	  cohort;	  a	  spontaneous	  abortion	  or	  stillbirth;	  b	  SGA/LBW/PTB	  or	  fetal	  loss	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Table	  S5:	  Adverse	  events	  	  
	   ISTp-­‐DP	   IPTp-­‐DP	   IPTp-­‐SP	  
Within	  30	  minutes	  following	  drug	  administration	  
Vomiting	  initial	  
dose	  (each	  course)	  
2/	  245	  (0.8%)	   4/	  1725	  (0.2%)	   3/	  1787	  (0.2%)	  
Vomiting	  repeat	  
dose	  
0/	  2	  (0%)	   3/	  4	  (75%)	   0/	  3	  (0%)	  
Tolerability	  1-­‐7	  days	  following	  drug	  administrationa	  
	   Eventsb	   IR	  (95%	  CI)c	   Eventsb	   IR	  (95%	  CI)c	   Eventsb	   IR	  (95%	  CI)c	  
Total	  number	  of	  
women	  who	  
received	  
medication	  at	  least	  
once	  (N)	  
187	   	   487	   	   487	   	  
Any	  reported	  drug	  
tolerability	  event	  
2	   45.4	  (11.4-­‐181.4)	   27	   83.8	  (57.4-­‐122.1)	   36	   108.2	  (78.1-­‐150.0)	  
Fever	   2	   45.4	  (11.35-­‐181.4)	   2	   6.2	  (1.6-­‐24.8)	   8	   24.1	  (12.0-­‐48.1)	  
Weakness	   0	   0	   3	   9.3	  (3.0-­‐28.9)	   10	   30.1	  (16.2-­‐55.9)	  
Headache	   2	   22.7	  (3.2-­‐161.1)	   8	   18.6	  (8.4-­‐41.4)	   14	   24.1	  (12.0-­‐48.1)	  
Abdominal	  pain	   1	   22.7	  (3.2-­‐161.1)	   18	   55.8	  (35.2-­‐88.6)	   17	   51.1	  (31.8-­‐82.2)	  
Muscle	  pain	   1	   22.7	  (3.2-­‐161.1)	   6	   18.6	  (8.4-­‐41.4)	   8	   24.1	  (12.0-­‐48.1)	  
Nausea	   0	   0	   4	   12.4	  (4.7-­‐33.1)	   3	   9.0	  (2.9-­‐28.0)	  
Rash	   0	   0	   0	   0	   1	   3.0	  (0.4-­‐21.3)	  
Diarrhea	   0	   0	   1	   3.1	  (0.4-­‐22.0)	   1	   3.0	  (0.4-­‐21.3)	  
Vomiting	   0	   0	   4	   12.4	  (4.7-­‐33.1)	   3	   9.0	  (2.9-­‐28.0)	  
a	  includes	  symptoms	  which	  were	  asked	  to	  all	  women	  presenting	  for	  unscheduled	  visits	  
b	  no	  woman	  had	  more	  than	  one	  event	  within	  seven	  days	  of	  drug	  administration,	  thus	  number	  of	  women	  is	  the	  same	  as	  the	  
number	  of	  events	  	  
c	  incidence	  rate	  per	  100	  person	  years
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Performance	  of	  RDTs	  in	  ISTp-­‐arm	  
Post-hoc analysis of the sensitivity of RDTs in the ISTp arm to detect PCR positive infections in the 
peripheral blood was 52.5% (95% CI 47.8-57.2%]) overall and 64.9% (58.6-71.3%) and 40.4% (33.9-
46.8%) in pauci,- and multigravidae, which could be explained by higher geometric mean parasite 
densities observed in paucigravidae: geometric mean (95% CI) 158 (88-283) compared to 33 (13-80) in 
multigravidae.  
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